TG Therapeutics Enters Global Partnership To Develop, Commercialize Novel BET Inhibitors Developed By Jubilant Biosys For Hematological Malignancy Treatments; Receives Upfront Licensing Fee Of $1M & Potential Milestones Of ~$177M